What is the PAWSS?
The Prediction of Alcohol Withdrawal Severity Scale (PAWSS) is a bedside screening tool developed by Maldonado and colleagues to identify hospitalized adults at elevated risk for complicated alcohol withdrawal syndrome (AWS) before severe manifestations develop. It was introduced in a systematic literature review and pilot validation study (Alcohol, 2014) and is widely used on general medical floors to complement, not replace, protocolized monitoring and symptom-triggered benzodiazepine therapy.
PAWSS differs from scales such as the Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar), which quantify active withdrawal symptoms during treatment. PAWSS is applied early in admission to stratify who may need prophylaxis, intensive monitoring, or symptom-triggered pathways based on history and presentation rather than waiting for full withdrawal to declare itself.
Each positive item contributes 1 point; the total ranges from 0 to 10. A score ≥ 4 indicates high risk for complicated AWS at the validated cutoff. PAWSS is an educational risk stratification aid and does not, by itself, dictate a specific drug, dose, or monitoring frequency.
Clinical context: alcohol withdrawal in hospitalized patients
Alcohol withdrawal occurs when a person with physiologic dependence on alcohol abruptly reduces or stops drinking. Central nervous system hyperexcitability results from loss of GABAergic inhibition and glutamatergic rebound. Manifestations span a spectrum from mild anxiety, tremor, and insomnia to life-threatening delirium tremens (DTs), withdrawal seizures, and withdrawal hallucinosis.
Complicated AWS carries substantial morbidity and mortality if undertreated. Hospitalized patients may present for unrelated medical or surgical illness while still dependent on alcohol; withdrawal risk is easily missed when the admission diagnosis is not alcohol-related. Standard CIWA-Ar monitoring is resource-intensive and is not always necessary for every drinker, yet inadequate prophylaxis in high-risk patients can lead to preventable seizures and ICU transfers.
PAWSS was designed to help clinicians select patients who warrant heightened vigilance and withdrawal-oriented care on a general medical unit, including those without a documented diagnosis of alcohol use disorder (AUD) in the chart.
Patient population and when to use PAWSS
Apply PAWSS in hospitalized adults aged 18 years or older admitted to a general medical floor (or equivalent inpatient setting), with or without a known history of AUD.
Threshold criteria must be met before scoring: the patient consumed any amount of alcohol within the last 30 days or had a positive blood alcohol level (BAL) on admission. If neither is true, PAWSS is not indicated and should not be scored.
Do not use PAWSS in patients with active or uncontrolled seizure disorder unrelated to alcohol withdrawal screening protocols at your institution. If withdrawal is clinically suspected despite failing the alcohol-exposure threshold, use appropriate clinical assessment and monitoring per local protocol rather than forcing a PAWSS score.
Threshold criteria (gate before scoring)
| Requirement | Action if not met |
|---|---|
| Alcohol within 30 days or positive admission BAL | PAWSS not applicable; do not sum the ten items |
| All ten items answered when threshold is met | Complete interview and clinical assessment before calculating total score |
Scoring: ten items (1 point per “Yes”)
After the threshold is satisfied, assign 1 point for each “Yes” and 0 for each “No.” Items are grouped into patient interview (history) and clinical evidence (presentation).
Patient interview (8 items)
| Item | Points if Yes |
|---|---|
| Recently intoxicated or drunk within the last 30 days | +1 |
| Prior alcohol use disorder treatment (inpatient, outpatient, rehabilitation, or Alcoholics Anonymous) | +1 |
| Prior episode(s) of alcohol withdrawal (any severity) | +1 |
| Prior alcohol-related blackouts | +1 |
| Prior alcohol withdrawal seizures | +1 |
| Prior delirium tremens (DTs) | +1 |
| Combined alcohol with other “downers” (e.g., benzodiazepines, barbiturates) in the last 90 days | +1 |
| Combined alcohol with any other substance of abuse in the last 90 days | +1 |
Clinical evidence (2 items)
| Item | Points if Yes |
|---|---|
| Blood alcohol level on presentation ≥ 200 mg/dL | +1 |
| Autonomic hyperactivity at evaluation (e.g., heart rate > 120 bpm, tremor, diaphoresis, agitation, nausea) | +1 |
Total PAWSS score = sum of all ten items (range 0 to 10).
What counts as “complicated” alcohol withdrawal?
PAWSS targets risk for complicated AWS, a composite that in the derivation work included:
- Withdrawal hallucinosis
- Withdrawal-related seizures
- Delirium tremens
Mild tremor, anxiety, or modest autonomic arousal without progression may still require treatment but represent a different management intensity than complicated courses. The scale helps anticipate who may cross into complicated territory during the hospital stay.
Risk interpretation
| PAWSS score | Risk category | Clinical implication |
|---|---|---|
| 0 to 3 | Lower risk for complicated AWS (at the <4 cutoff) | Continue routine clinical monitoring; complicated withdrawal can still occur. Symptom-triggered therapy may be appropriate per local protocol. Repeat assessment if clinical status changes. |
| ≥ 4 | High risk for complicated AWS | In validation work this cutoff had a high likelihood ratio for complicated withdrawal. Consider prophylaxis and/or treatment per institutional AWS protocol; heightened vigilance; evaluate candidacy for CIWA-Ar or equivalent symptom-triggered monitoring. |
| N/A (threshold not met) | PAWSS not indicated | Do not apply the ten-item score. If withdrawal is still suspected, use clinical judgment and appropriate assessment pathways. |
PAWSS stratifies risk at admission; it does not eliminate the need for ongoing vital signs, mental status checks, and reassessment as alcohol clears and withdrawal emerges (often 6 to 24 hours or later after last drink).
Rationale for individual items
- Recent intoxication: Reflects ongoing heavy use and short interval to withdrawal after cessation.
- Prior AUD treatment: Surrogate for more severe, chronic use patterns and prior engagement with the medical consequences of drinking.
- Prior withdrawal episodes: History of withdrawal predicts future withdrawal; prior severity often escalates over time.
- Blackouts: Marker of high-quantity consumption and neurotoxic exposure.
- Prior withdrawal seizures and DTs: Strongest historical predictors of complicated recurrence; prior DTs especially warrant aggressive prophylaxis.
- Combined alcohol with downers or other substances: Polysubstance use complicates sedation strategies, clouding clinical assessment and increasing autonomic instability.
- BAL ≥ 200 mg/dL on presentation: High admission level correlates with heavy recent intake and delayed, severe withdrawal as levels fall.
- Autonomic hyperactivity at evaluation: Early hyperadrenergic signs (tachycardia, tremor, diaphoresis, agitation, nausea) may indicate withdrawal already underway or imminent as BAL declines.
Management pathways after PAWSS
Institutional protocols vary, but general principles aligned with the CalcMD calculator recommendations include:
- Score ≥ 4: Consider prophylaxis and/or treatment for alcohol withdrawal per protocol; place the patient on symptom-triggered therapy when appropriate; use clinical judgment to determine CIWA-Ar or alternative monitoring; do not rely on PAWSS alone.
- Score < 4: Maintain vigilance for emerging signs; repeat assessment if new tremor, agitation, hypertension, or delirium develops; monitoring intensity should still follow presentation and nursing concerns.
- All scores: Treat emergent symptoms (seizure, severe agitation, hemodynamic collapse) immediately regardless of screening result.
Benzodiazepines remain the cornerstone of AWS treatment in most hospitals, using fixed-schedule, symptom-triggered (CIWA-Ar driven), or front-loading strategies per protocol. Thiamine, folate, magnesium, and correction of electrolyte abnormalities are adjuncts for comorbid nutritional and metabolic disease. Phenobarbital or ICU-level care may be required for refractory cases per specialist guidance.
Relationship to CIWA-Ar and other tools
CIWA-Ar measures severity of active withdrawal (nausea, tremor, paroxysmal sweats, anxiety, agitation, tactile/auditory/visual disturbances, headache, orientation) and guides benzodiazepine dosing during established withdrawal. PAWSS predicts who is likely to develop complicated withdrawal and may benefit from being on such a pathway early.
A practical workflow is: apply PAWSS at admission when threshold criteria are met; for high-risk patients, initiate protocolized monitoring (often CIWA-Ar or an institutional equivalent) and prophylaxis; for lower-risk patients, use nursing observation with a low threshold to escalate if symptoms appear.
Important limitations
- Screening, not diagnosis: PAWSS does not confirm current withdrawal syndrome or exclude other causes of agitation, tachycardia, or delirium (infection, metabolic derangement, intracranial pathology).
- Self-report dependence: Interview items require accurate history; intoxication, cognitive impairment, and stigma may limit disclosure.
- Single time point: Risk changes as BAL falls; a low score at admission does not guarantee an uncomplicated course 24 to 48 hours later.
- Not validated in all settings: Derivation focused on hospitalized medical patients; caution when extrapolating to ICU, ED-only assessment without admission, or detoxification-only units without local validation.
- Excludes uncontrolled seizure disorder: By design; these patients require separate neurological and withdrawal management frameworks.
- Does not specify benzodiazepine choice or dose: Follow institutional AWS order sets and addiction medicine consultation when available.
- Complicated withdrawal can occur at any score: The <4 group is lower risk at the cutoff, not zero risk.
Documentation and workflow tips
Document whether threshold criteria were met, each of the ten items with Yes/No responses, the total PAWSS score, risk category, and the planned monitoring pathway (observation vs CIWA-Ar vs prophylaxis). Record BAL when available, time of last drink if known, and whether addiction psychiatry or social work was consulted. Re-score or escalate care if new autonomic signs, confusion, or hallucinations develop during the admission.
Using this CalcMD calculator
Confirm threshold criteria (alcohol within 30 days or positive admission BAL). If met, answer all ten yes/no items from patient interview and clinical assessment. The tool computes the total score (0 to 10), classifies high risk (≥ 4) versus lower risk (< 4), or displays not applicable when the threshold is absent, with item-by-item breakdown and management-oriented recommendations aligned to lib/pawss.ts.
Use the output for education, admission documentation, and nursing handoff. It does not replace institutional protocols, toxicology consultation, or emergency treatment of acute withdrawal complications.